UBS Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-295
Closed -$1K 8496
2017
Q4
$1K Sell
295
-1,475
-83% -$6.04K ﹤0.01% 7789
2017
Q3
$7K Buy
1,770
+918
+108% +$3.51K ﹤0.01% 7117
2017
Q2
$3K Sell
852
-11,970
-93% -$47.5K ﹤0.01% 7340
2017
Q1
$53K Buy
12,822
+12,576
+5,112% +$52.9K ﹤0.01% 5491
2016
Q4
$1K Sell
246
-6,971
-97% -$45.1K ﹤0.01% 7698
2016
Q3
$71K Buy
+7,217
New +$51.2K ﹤0.01% 5238
2016
Q2
Sell
-1,331
Closed -$10K 8181
2016
Q1
$10K Buy
+1,331
New +$10.2K ﹤0.01% 6683
2015
Q3
Sell
-2,785
Closed -$62K 8852
2015
Q2
$62K Buy
2,785
+2,635
+1,757% +$41.7K ﹤0.01% 5821
2015
Q1
$1K Sell
150
-2,758
-95% -$27K ﹤0.01% 8631
2014
Q4
$33K Buy
+2,908
New +$31.6K ﹤0.01% 7016

UBS Group's CASC Position: Q1 2018 in Review

UBS Group sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 295 shares — an estimated $1K sold.

UBS Group first reported a position in CASC in Q4 2014 and held it in 10 quarters. The position peaked at $71K in Q3 2016. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • UBS Group reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • UBS Group sold 295 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $1K.
  • UBS Group first reported a position in Cascadian Therapeutics, Inc. in Q4 2014 and held it in 10 quarters.
  • UBS Group's Cascadian Therapeutics, Inc. position peaked at $71K in Q3 2016.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on UBS Group's 13F filing for Q1 2018, filed 15 May 2018.